Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Jaguar Health, Inc. on May 14, 2018, with the earliest event reported on that date. The filing covers corporate governance updates, the results of the 2018 Annual Meeting of Stockholders held on May 18, 2018, and a critical regulatory status update regarding Nasdaq listing compliance.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate actions and governance rather than financial performance metrics.
Material Changes and Corporate Actions
- Compensation Plans Approved: On May 14, 2018, the Board approved a 2018 Bonus Plan and a Severance Plan for senior executive officers (CEO, CFO, and Executive Vice President).
- Bonus Plan Details: Bonuses are based on individual and corporate goals. The maximum award is 125% of the target bonus.
- Severance Plan Details: Provides 12 months of base salary, 100% accelerated vesting of stock options, a one-year extension on option exercise periods, and 12 months of COBRA premiums upon a "Qualifying Termination" (termination without cause or change of control after meeting financial hurdles).
- Stockholder Vote Results: Four proposals were approved at the Annual Meeting:
- Ratification of BDO USA, LLP as independent auditors.
- Removal of the 19.99% limitation on the conversion of Series A Convertible Participating Preferred Stock.
- Authorization of a reverse stock split between 1-for-11 and 1-for-15.
- Reduction of authorized Common Stock to 150,000,000 shares, contingent on the reverse split.
Outlook, Risks, and Contingencies
Nasdaq Delisting Risk: The Company received notice from Nasdaq on May 15, 2018, that it failed to meet the minimum bid price requirement ($1.00 per share) during its second 180-day grace period, which expired on May 14, 2018. Consequently, the Company's securities are subject to delisting.
Remediation Plan: The Company intends to request a hearing before the Nasdaq Hearings Panel to present a plan to regain compliance via a 1-for-15 reverse stock split, utilizing authority granted by stockholders. A timely hearing request will stay delisting actions pending the outcome.
Forward-Looking Statements: The Company explicitly states there is no assurance it will regain compliance, that Nasdaq will grant relief, or that it will meet applicable listing requirements in the future.
Investor Verification Checklist
- Verify the exact reverse stock split ratio (between 1-for-11 and 1-for-15) once announced by the Board by June 30, 2018.
- Monitor the status of the hearing request with the Nasdaq Hearings Panel and the subsequent decision on continued listing.
- Review the full text of the Severance Plan (Exhibit 99.1) for specific financial hurdles related to preferred stock conversion.
- Confirm the impact of the 19.99% limitation removal on the voting power and dilution of common stockholders upon preferred stock conversion.